JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vale, M. L.
Right arrow Articles by Ribeiro, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vale, M. L.
Right arrow Articles by Ribeiro, R. A.

Vol. 304, Issue 1, 102-108, January 2003

Antinociceptive Effects of Interleukin-4, -10, and -13 on the Writhing Response in Mice and Zymosan-Induced Knee Joint Incapacitation in Rats

Mariana L. Vale, Jaciara B. Marques, Camila A. Moreira, Francisco Aírton C. Rocha, Sérgio H. Ferreira, Stephen Poole, Fernando Q. Cunha and Ronaldo A. Ribeiro

Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil (M.L.V., J.B.M., C.A.M., F.A.C.R., R.A.R.); Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Sao Paolo, Brazil (S.H.F., F.Q.C.); and Endocrinology Section, National Institute for Biological Standards and Control, London, United Kingdom (S.P.)

The antinociceptive effects of interleukin (IL)-4, -10, and -13 were investigated in two different experimental pain models. Our results showed that pretreatment (30 min) with IL-4 (1-5 ng/animal), IL-10 (0.4-10 ng/animal), or IL-13 (0.4-2.5 ng/animal) inhibited the writhing response induced by the i.p. administration of acetic acid (53-89%) or zymosan (63-74%) in mice, and the knee joint incapacitation induced by i.a. injection of zymosan (49-66%) in rats. Neither of the cytokines affected the pain elicited in mice using the hot-plate test. This analgesic effect of IL-4, -10, and -13 was not reversed by the combined pretreatment with the opioid receptor antagonist naloxone. IL-4, -10, or -13 significantly inhibited the release of both tumor necrosis factor (TNF)-alpha (60, 53, and 100%, respectively) and IL-1beta (80, 100, and 100%, respectively) by mice peritoneal macrophages obtained after local (i.p.) injection of zymosan. Antisera against IL-4, -10, and -13 potentiated both the zymosan-induced writhing response and the articular incapacitation. Our results demonstrate that IL-4, -10, and -13 display analgesic activity that is probably not due to endogenous opioid release. This analgesic effect could be related to a peripheral mechanism, probably via the inhibition of the release of the pro-inflammatory cytokines TNF-alpha and IL-1beta by resident peritoneal macrophages.


0022-3565/03/3041-0102$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
W. A. Verri Jr., A. T. G. Guerrero, S. Y. Fukada, D. A. Valerio, T. M. Cunha, D. Xu, S. H. Ferreira, F. Y. Liew, and F. Q. Cunha
IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice
PNAS, February 19, 2008; 105(7): 2723 - 2728.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. I. Svensson, M. Zattoni, and C. N. Serhan
Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing
J. Exp. Med., February 19, 2007; 204(2): 245 - 252.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.